Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Sanofi India sells...

    Sanofi India sells oldest facility at Ankleshwar to Advent for Rs 262 crore

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-09-12T17:41:07+05:30  |  Updated On 2021-08-13T17:21:12+05:30

    The Ankleshwar site is Sanofi India's oldest manufacturing facility where brands like Combiflam, Allegra and Amaryl are made. The production of these iconic brands will now be moved to the Company's Goa site and external manufacturing sites as well.


    Mumbai: Drug major, Sanofi India has sold its oldest manufacturing facility, at Ankleshwar to Advent International for Rs 262 crore.


    The Board of Directors of Sanofi India Limited (SIL) has approved a transaction for the slump sale and transfer of its manufacturing facility at Ankleshwar, Gujarat to Zentiva and its legal entity in India, Zentiva Private Limited for a consideration of Rs. 2,617 million, subject to customary working capital adjustments. This transaction is subject to shareholders' approval and the completion of certain conditions as defined under the Business Transfer Agreement.


    In 2018, as part of a global transaction, Zentiva, which was Sanofi's European generics business, was sold to Advent International.


    The Ankleshwar site is Sanofi India's oldest manufacturing facility where brands like Combiflam, Allegra and Amaryl are made. The production of these iconic brands will now be moved to the Company's Goa site and external manufacturing sites as well.


    Read Also: Sanofi revival depends on the outsider with a nose for big drugs: Report


    Ankleshwar site was established in 1987. It has a chemistry & biotechnology development centre and manufactures both intermediates and pharmaceutical formulations. A large producer of tablets, Sanofi's Ankleshwar site manufactures more than 6 billion tablets annually.


    Commenting on the same, Rajaram NARAYANAN, Managing Director – Sanofi India Limited said, "Sanofi's long-term strategy is to focus on manufacturing Sanofi branded products. Given that the two companies share similar values and commitment towards serving patients and their employees, the Board of Directors of Sanofi India Limited approved this transaction in the long-term interest of all stakeholders."


    Read Also: Philippines weighs re-use of Sanofi controversial dengue vaccine Dengvaxia

    Advent International Allegra Amaryl Ankleshwar Combiflam global transaction pharma pharma company pharma news pharma news india Rajaram narayanan Sanofi sanofi goa facility sanofi gujarat facility sanofi MD SIL Zentiva 

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop...

      Top priority on Delivery of Medicines through Speed Post: Minister

      Top priority on Delivery of Medicines through Speed Post: Minister

      Shipment of  antimalarial drug to US is likely to start next week: Indian Pharmaceutical Alliance

      Shipment of antimalarial drug to US is likely to start next week: Indian Pharmaceutical Alliance

      Lupin gets USFDA EIR for Nagpur Facility

      Lupin gets USFDA EIR for Nagpur Facility

      NPPA fixes prices of 29 formulations under DPCO, check out details

      NPPA fixes prices of 29 formulations under DPCO, check out details

      Coronavirus pandemic: Govt delegates more powers to NPPA to control, increase API production by manufacturers

      Coronavirus pandemic: Govt delegates more powers to NPPA to control, increase API production by...

      Aurobindo Pharma gets USFDA nod for Fluoxetine Tablets

      Aurobindo Pharma gets USFDA nod for Fluoxetine Tablets

      Aurobindo Pharma faces CA Suit in US for concealing facts

      Aurobindo Pharma faces CA Suit in US for concealing facts

      Jubilant Life Sciences Karnataka plant shut on coronavirus scare

      Jubilant Life Sciences Karnataka plant shut on coronavirus scare

      IPA releases Best Practices for Employee Safety in Pharmaceutical Manufacturing during COVID-19

      IPA releases Best Practices for Employee Safety in Pharmaceutical Manufacturing during COVID-19

      Coronavirus Impact: Indian Pharma Exports to miss 22 Billion target, says Pharmexcil

      Coronavirus Impact: Indian Pharma Exports to miss 22 Billion target, says Pharmexcil

      Bharat Biotech join hands with University of Wisconsin, FluGen for COVID-19 vaccine- CoroFlu

      Bharat Biotech join hands with University of Wisconsin, FluGen for COVID-19 vaccine- CoroFlu

      USFDA Requests Removal of All Ranitidine Products (Zantac) from the Market

      USFDA Requests Removal of All Ranitidine Products (Zantac) from the Market

      Popular Stories

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      Sterling Biotech Bank Fraud: ED seize assets including business jet, ships, oil rings worth over Rs 9700 crore

      Sterling Biotech Bank Fraud: ED seize assets including business jet, ships, oil rings worth over Rs...

      3.36% of about 82,600 drugs samples found to be substandard

      3.36% of about 82,600 drugs samples found to be substandard

      Johnson n Johnson ties up with CSIR-IMTECH to Develop Innovative Tuberculosis Treatments

      Johnson n Johnson ties up with CSIR-IMTECH to Develop Innovative Tuberculosis Treatments

      Bring Cataract Lenses, Syringes, IV Fluid Sets, Urine Bags under Price Ceiling: Maha Govt tells Health Ministry

      Bring Cataract Lenses, Syringes, IV Fluid Sets, Urine Bags under Price Ceiling: Maha Govt tells...

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      View All

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 27 May 2022 6:45 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X